<DOC>
	<DOCNO>NCT02027727</DOCNO>
	<brief_summary>The purpose study determine early infliximab pharmacokinetic level associate clinical remission week 30 54 pediatric IBD patient .</brief_summary>
	<brief_title>Individualized Infiximab Dosing-Proof Concept Study</brief_title>
	<detailed_description>Our aim : 1. determine early pk level ; week 6 ( peak ) , week 8 ( 2 week ) week 14 ( trough ) , associate week 30 54 outcome pediatric IBD patient . 2. determine forecast PK determine newly develop Population PK Model software program agreement observe PK IBD patient receive infliximab . Subject recruitment limit patient principal investigator . Subjects approach participation research person routine clinic visit member study team .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>1 . Males females IFX 2 . Patients IBD 3 . Age 623 4 . Able obtain consent 1 . Not receive infliximab 2 . On 10 mg/kg IFX 3 . Not able obtain consent</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>infliximab</keyword>
	<keyword>trough level</keyword>
	<keyword>crohn 's disease</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>